Medicinova Inc SEC filings MNOV
Medicinova Inc has 879 filings in SEC EDGAR's recent list, going back to Apr 8, 2003. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 28, 2026 (material agreement). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 29, 2026 | — |
| DEF 14A | Proxy statement | Apr 29, 2026 | Jun 23, 2026 |
| PRE 14A | Preliminary proxy statement | Apr 17, 2026 | Jun 23, 2026 |
| DEFA14A | Additional proxy material | Apr 28, 2025 | — |
| DEF 14A | Proxy statement | Apr 28, 2025 | Jun 17, 2025 |
| DEFA14A | Additional proxy material | Apr 26, 2024 | — |
| DEF 14A | Proxy statement | Apr 26, 2024 | Jun 11, 2024 |
| DEFA14A | Additional proxy material | Apr 26, 2023 | — |
| DEF 14A | Proxy statement | Apr 26, 2023 | Jun 13, 2023 |
| DEFA14A | Additional proxy material | Apr 26, 2022 | — |
| DEF 14A | Proxy statement | Apr 26, 2022 | Jun 14, 2022 |
| DEFA14A | Additional proxy material | Apr 27, 2021 | — |
| DEF 14A | Proxy statement | Apr 27, 2021 | Jun 16, 2021 |
| DEFA14A | Additional proxy material | Apr 28, 2020 | — |
| DEF 14A | Proxy statement | Apr 27, 2020 | Jun 16, 2020 |
| DEFA14A | Additional proxy material | May 1, 2019 | — |
| DEF 14A | Proxy statement | Apr 26, 2019 | Jun 10, 2019 |
| DEFA14A | Additional proxy material | May 9, 2018 | — |
| DEFA14A | Additional proxy material | Apr 26, 2018 | — |
| DEF 14A | Proxy statement | Apr 26, 2018 | Jun 7, 2018 |
| DEF 14A | Proxy statement | Apr 27, 2017 | Jun 8, 2017 |
| DEF 14A | Proxy statement | Apr 27, 2016 | Jun 9, 2016 |
| DEF 14A | Proxy statement | Apr 29, 2015 | Jun 11, 2015 |
| DEF 14A | Proxy statement | Apr 29, 2014 | Jun 13, 2014 |
| DEF 14A | Proxy statement | Apr 29, 2013 | Jun 14, 2013 |
| DEF 14A | Proxy statement | Apr 30, 2012 | Jun 14, 2012 |
| PRE 14A | Preliminary proxy statement | Apr 17, 2012 | Jun 14, 2012 |
| DEF 14A | Proxy statement | Apr 29, 2011 | Jun 14, 2011 |
| DEF 14A | Proxy statement | Apr 29, 2010 | Jun 10, 2010 |
| DEF 14A | Proxy statement | Apr 29, 2009 | Jun 11, 2009 |
| DEF 14A | Proxy statement | Apr 29, 2008 | Jun 6, 2008 |
| PRE 14A | Preliminary proxy statement | Apr 14, 2008 | Jun 6, 2008 |
| DEF 14A | Proxy statement | Mar 13, 2007 | Mar 14, 2007 |
| PRE 14A | Preliminary proxy statement | Feb 20, 2007 | Mar 30, 2007 |
| DEFA14A | Additional proxy material | Oct 4, 2006 | — |
| DEF 14A | Proxy statement | Sep 8, 2006 | Oct 13, 2006 |
| PRE 14A | Preliminary proxy statement | Aug 9, 2006 | Oct 6, 2006 |
| DEF 14A | Proxy statement | Apr 13, 2006 | May 4, 2006 |
| DEF 14A | Proxy statement | Jun 7, 2005 | Jul 19, 2005 |
Showing 39 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MNOV (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- La Jolla, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1226616
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.